NO3024833T3 - - Google Patents

Info

Publication number
NO3024833T3
NO3024833T3 NO14758605A NO14758605A NO3024833T3 NO 3024833 T3 NO3024833 T3 NO 3024833T3 NO 14758605 A NO14758605 A NO 14758605A NO 14758605 A NO14758605 A NO 14758605A NO 3024833 T3 NO3024833 T3 NO 3024833T3
Authority
NO
Norway
Application number
NO14758605A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50023640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO3024833(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO3024833T3 publication Critical patent/NO3024833T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO14758605A 2013-07-23 2014-07-22 NO3024833T3 (cg-RX-API-DMAC7.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1357265A FR3008976A1 (fr) 2013-07-23 2013-07-23 "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
PCT/FR2014/051885 WO2015011397A1 (fr) 2013-07-23 2014-07-22 Nouveaux dérivés d'indolizine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
NO3024833T3 true NO3024833T3 (cg-RX-API-DMAC7.html) 2018-02-03

Family

ID=50023640

Family Applications (1)

Application Number Title Priority Date Filing Date
NO14758605A NO3024833T3 (cg-RX-API-DMAC7.html) 2013-07-23 2014-07-22

Country Status (50)

Country Link
US (3) US9944620B2 (cg-RX-API-DMAC7.html)
EP (1) EP3024833B1 (cg-RX-API-DMAC7.html)
JP (1) JP6458029B2 (cg-RX-API-DMAC7.html)
KR (1) KR102007516B1 (cg-RX-API-DMAC7.html)
CN (1) CN105579450B (cg-RX-API-DMAC7.html)
AP (1) AP2016008990A0 (cg-RX-API-DMAC7.html)
AR (1) AR099913A1 (cg-RX-API-DMAC7.html)
AU (1) AU2014294867B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016001328B1 (cg-RX-API-DMAC7.html)
CA (1) CA2918217C (cg-RX-API-DMAC7.html)
CL (1) CL2016000063A1 (cg-RX-API-DMAC7.html)
CR (1) CR20160031A (cg-RX-API-DMAC7.html)
CU (1) CU24380B1 (cg-RX-API-DMAC7.html)
CY (1) CY1119652T1 (cg-RX-API-DMAC7.html)
DK (1) DK3024833T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2016000014A (cg-RX-API-DMAC7.html)
EA (1) EA030323B1 (cg-RX-API-DMAC7.html)
ES (1) ES2650814T3 (cg-RX-API-DMAC7.html)
FR (1) FR3008976A1 (cg-RX-API-DMAC7.html)
GE (1) GEP20176804B (cg-RX-API-DMAC7.html)
GT (1) GT201600017A (cg-RX-API-DMAC7.html)
HK (1) HK1222394A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20171752T1 (cg-RX-API-DMAC7.html)
HU (1) HUE037498T4 (cg-RX-API-DMAC7.html)
IL (1) IL243742B (cg-RX-API-DMAC7.html)
JO (1) JO3310B1 (cg-RX-API-DMAC7.html)
LT (1) LT3024833T (cg-RX-API-DMAC7.html)
MA (1) MA38803A1 (cg-RX-API-DMAC7.html)
MD (1) MD4643C1 (cg-RX-API-DMAC7.html)
ME (1) ME02922B (cg-RX-API-DMAC7.html)
MX (1) MX365916B (cg-RX-API-DMAC7.html)
MY (1) MY178251A (cg-RX-API-DMAC7.html)
NI (1) NI201600015A (cg-RX-API-DMAC7.html)
NO (1) NO3024833T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ716156A (cg-RX-API-DMAC7.html)
PE (1) PE20160240A1 (cg-RX-API-DMAC7.html)
PH (1) PH12016500057B1 (cg-RX-API-DMAC7.html)
PL (1) PL3024833T3 (cg-RX-API-DMAC7.html)
PT (1) PT3024833T (cg-RX-API-DMAC7.html)
RS (1) RS56451B1 (cg-RX-API-DMAC7.html)
RU (1) RU2693629C2 (cg-RX-API-DMAC7.html)
SA (1) SA516370448B1 (cg-RX-API-DMAC7.html)
SG (2) SG10201800580XA (cg-RX-API-DMAC7.html)
SI (1) SI3024833T1 (cg-RX-API-DMAC7.html)
TN (1) TN2016000014A1 (cg-RX-API-DMAC7.html)
TW (1) TWI511969B (cg-RX-API-DMAC7.html)
UA (1) UA119243C2 (cg-RX-API-DMAC7.html)
UY (1) UY35626A (cg-RX-API-DMAC7.html)
WO (1) WO2015011397A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201600350B (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2986002B1 (fr) 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008976A1 (fr) * 2013-07-23 2015-01-30 Servier Lab "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
WO2018015526A1 (en) 2016-07-22 2018-01-25 Les Laboratoires Servier Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof
WO2018158225A1 (en) 2017-02-28 2018-09-07 Les Laboratoires Servier Combination of a bcl-2 inhibitor and a mdm2 inhibitor, uses and pharmaceutical compositions thereof
RU2764243C2 (ru) 2017-09-22 2022-01-14 ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи Гетероциклические соединения в качестве ингибиторов PAD
CN111225915B (zh) 2017-10-18 2023-03-07 朱比兰特埃皮帕德有限公司 作为pad抑制剂的咪唑并吡啶化合物
FR3072679B1 (fr) * 2017-10-25 2020-10-30 Servier Lab Nouveaux derives macrocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US11629135B2 (en) 2017-11-06 2023-04-18 Jubilant Prodell Llc Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
RS65576B1 (sr) 2017-11-24 2024-06-28 Jubilant Episcribe Llc Heterociklična jedinjenja kao inhibitori prmt5
CN112105610B (zh) 2018-03-13 2024-01-26 朱比连特普罗德尔有限责任公司 作为pd1/pd-l1相互作用/活化的抑制剂的双环化合物
US11814734B2 (en) * 2019-05-13 2023-11-14 Ecolab Usa Inc. 1,2,4-triazolo[1,5-a] pyrimidine derivative as copper corrosion inhibitor
CN116981458A (zh) * 2021-03-12 2023-10-31 伊尔治疗学股份有限公司 具有四氢吲哚-1-甲酰胺作为bcl-2抑制剂的化合物
WO2023129553A1 (en) * 2021-12-29 2023-07-06 Eil Therapeutics, Inc. Bcl-2 inhibitors
IL317101A (en) 2022-05-20 2025-01-01 Novartis Ag Antibody-drug conjugates of anticancer compounds and methods of using them
AR134424A1 (es) 2023-11-22 2026-01-14 Novartis Ag Conjugados de anticuerpo anti-cd7-fármaco y métodos de uso de los mismos
UY40985A (es) 2023-11-22 2025-06-30 Servier Lab Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100391958C (zh) * 2001-09-19 2008-06-04 安万特医药股份有限公司 化合物
AU2003234464B2 (en) 2002-05-03 2009-06-04 Exelixis, Inc. Protein kinase modulators and methods of use
US20050070570A1 (en) 2003-06-18 2005-03-31 4Sc Ag Novel potassium channels modulators
BRPI0514504A (pt) * 2004-08-20 2008-06-10 Univ Michigan pequenas moléculas inibidoras de membros da famìlia bcl-2 anti-apoptóticos e os usos das mesmas
CN101039662A (zh) * 2004-08-20 2007-09-19 密执安州立大学董事会 抗-细胞凋亡bcl-2家族成员的小分子抑制剂及其应用
WO2007075783A2 (en) 2005-12-22 2007-07-05 Wyeth Substituted isoquinoline-1,3(2h,4h)-diones, 1-thioxo-1,4-dihydro-2h-isoquinoline-3-ones and 1,4-dihydro-3(2h)-isoquinolones and use thereof as kinase inhibitor
US7902218B2 (en) 2006-12-12 2011-03-08 Bristol-Myers Squibb Company Substituted tetrahydroisoquinolines as β-secretase inhibitors
KR101511074B1 (ko) 2007-04-16 2015-04-13 애브비 인코포레이티드 7-치환된 인돌 Mcl-1 억제제
US8263607B2 (en) 2007-05-22 2012-09-11 Astellas Pharma Inc. 1-substituted tetrahydroisoquinoline compound
CN102007101A (zh) 2007-11-30 2011-04-06 生物区科学管理控股有限公司 作为抗菌剂的四氢-异喹啉ppat抑制剂
JP5496915B2 (ja) 2008-02-13 2014-05-21 シージーアイ ファーマシューティカルズ,インコーポレーテッド 6−アリール−イミダゾ[1,2−a]ピラジン誘導体、その製造方法、及びその使用方法
WO2009102488A2 (en) 2008-02-15 2009-08-20 Tufts University A humanized model of membrane attack complex (mac) formation on murine retina and compositions, kits and methods for treatment of macular degeneration
CN103732589B (zh) * 2011-05-25 2016-03-30 百时美施贵宝公司 可用作抗细胞凋亡bcl抑制剂的取代的磺酰胺
AU2012355623A1 (en) 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
EA201491265A1 (ru) 2011-12-23 2014-11-28 Новартис Аг Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию
AU2012355624A1 (en) 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
AU2012355613A1 (en) 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
CA2859873A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
DK2609926T3 (da) 2011-12-30 2014-01-06 Jakob Hraschan Forebyggelse eller behandling af smertefulde polyneuropatier ved administration af et aluminiumsilikat
FR2986002B1 (fr) 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008976A1 (fr) * 2013-07-23 2015-01-30 Servier Lab "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
FR3008979B1 (fr) * 2013-07-23 2015-07-24 Servier Lab Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
CL2016000063A1 (es) 2016-08-19
UY35626A (es) 2015-02-27
SG11201600318RA (en) 2016-02-26
TWI511969B (zh) 2015-12-11
RU2693629C2 (ru) 2019-07-03
UA119243C2 (uk) 2019-05-27
KR20160034387A (ko) 2016-03-29
RU2016105999A (ru) 2017-08-28
JP2016525536A (ja) 2016-08-25
PH12016500057A1 (en) 2016-03-28
AU2014294867A1 (en) 2016-02-11
MY178251A (en) 2020-10-07
RS56451B1 (sr) 2018-01-31
US9944620B2 (en) 2018-04-17
US20180186771A1 (en) 2018-07-05
BR112016001328A2 (cg-RX-API-DMAC7.html) 2017-07-25
NZ716156A (en) 2019-05-31
HUE037498T2 (hu) 2018-08-28
WO2015011397A1 (fr) 2015-01-29
CN105579450B (zh) 2017-12-12
HK1222394A1 (zh) 2017-06-30
TN2016000014A1 (fr) 2017-07-05
JO3310B1 (ar) 2018-09-16
HRP20171752T1 (hr) 2017-12-29
PE20160240A1 (es) 2016-04-30
GT201600017A (es) 2018-10-08
CA2918217A1 (fr) 2015-01-29
RU2016105999A3 (cg-RX-API-DMAC7.html) 2018-04-28
US20160176848A1 (en) 2016-06-23
MD20160016A2 (ro) 2016-07-31
EP3024833B1 (fr) 2017-09-06
NI201600015A (es) 2016-02-11
MX2016000906A (es) 2016-05-05
TW201504238A (zh) 2015-02-01
MD4643B1 (ro) 2019-08-31
AU2014294867B2 (en) 2018-10-04
ZA201600350B (en) 2017-05-31
JP6458029B2 (ja) 2019-01-23
AR099913A1 (es) 2016-08-31
EP3024833A1 (fr) 2016-06-01
ME02922B (me) 2018-04-20
EA030323B1 (ru) 2018-07-31
BR112016001328B1 (pt) 2022-03-03
PL3024833T3 (pl) 2018-02-28
MA38803A1 (fr) 2017-10-31
US10414754B2 (en) 2019-09-17
MD4643C1 (ro) 2020-03-31
SI3024833T1 (sl) 2017-12-29
PT3024833T (pt) 2017-10-06
SG10201800580XA (en) 2018-03-28
LT3024833T (lt) 2017-10-25
GEP20176804B (en) 2018-01-10
CR20160031A (es) 2016-04-04
ES2650814T3 (es) 2018-01-22
KR102007516B1 (ko) 2019-08-05
CN105579450A (zh) 2016-05-11
MX365916B (es) 2019-06-20
CY1119652T1 (el) 2018-04-04
US20190359595A1 (en) 2019-11-28
IL243742B (en) 2019-06-30
FR3008976A1 (fr) 2015-01-30
HUE037498T4 (hu) 2018-11-28
CU24380B1 (es) 2019-02-04
AP2016008990A0 (en) 2016-01-31
EA201600124A1 (ru) 2016-07-29
DOP2016000014A (es) 2016-03-15
PH12016500057B1 (en) 2016-03-28
DK3024833T3 (en) 2017-12-18
HK1223360A1 (zh) 2017-07-28
CA2918217C (fr) 2018-06-12
CU20160011A7 (es) 2016-05-30
SA516370448B1 (ar) 2018-12-12
IL243742A0 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
AP2016009275A0 (cg-RX-API-DMAC7.html)
BR112015007533A2 (cg-RX-API-DMAC7.html)
BR112014017733A2 (cg-RX-API-DMAC7.html)
BR112014017739A2 (cg-RX-API-DMAC7.html)
BR112014019326A2 (cg-RX-API-DMAC7.html)
BR112014018502A2 (cg-RX-API-DMAC7.html)
BR112014018516A2 (cg-RX-API-DMAC7.html)
BR112014017765A2 (cg-RX-API-DMAC7.html)
BR112014018480A2 (cg-RX-API-DMAC7.html)
BR112014017855A2 (cg-RX-API-DMAC7.html)
BR112014020341A2 (cg-RX-API-DMAC7.html)
BR112014021878A2 (cg-RX-API-DMAC7.html)
BR112014018468A2 (cg-RX-API-DMAC7.html)
BR112014018207A2 (cg-RX-API-DMAC7.html)
BR112014019204A2 (cg-RX-API-DMAC7.html)
BR112014017901A2 (cg-RX-API-DMAC7.html)
RU2016105999A3 (cg-RX-API-DMAC7.html)
BR112014017745A2 (cg-RX-API-DMAC7.html)
BR112014017794A2 (cg-RX-API-DMAC7.html)
BR112014017653A2 (cg-RX-API-DMAC7.html)
BR112014017601A2 (cg-RX-API-DMAC7.html)
BR112015015312A2 (cg-RX-API-DMAC7.html)
BR112014024039A2 (cg-RX-API-DMAC7.html)
BR112014018353A2 (cg-RX-API-DMAC7.html)
BR112014019048A2 (cg-RX-API-DMAC7.html)